home / subscribe / donate / books / archives / search / links / feedback / events / faq
Inside the New Print Edition of Our Subscriber-Only Newsletter!
50 Years After The Flight of the Dalai Lama, Where is Tibet Today?
Half a century ago this month the Dalai Lama fled Tibet as the People’s Liberation Army seized control of Lhasa. Today Beijing orders official rejoicing for the anniversary of “emancipation day for a million serfs”, even as Tibetans chafe under Beijing’s boot. In a brilliant report Chaohua Wang reports on the struggle for the future of Tibet. ALSO, Alexander Cockburn addresses the big question: How prepared is the left with ideas and programs in these days of crisis? It has the opportunity to change the face of America, down to the shopping malls. Is it ready? Get your new edition today by subscribing online or calling 1-800-840-3683 Contributions to CounterPunch are tax-deductible. Click here to make a donation. If you find our site useful please: Subscribe Now! CounterPunch books and gear make great presents.
|
Today's Stories March 13 / 15, 2009 Peter Lee Diana Johnstone March 12 , 2009 Sharon Smith Christopher Ketcham Mike Whitney Ray McGovern Eric Toussaint / John Ross M. Reza Pirbhai Chris Floyd Steve Early Quentin Gee Website of the Day March 11 , 2009 Mike Roselle Paul Craig Roberts Henry A. Giroux Nikolas Kozloff Norm Kent Mitu Sengupta Ludwig Watzal David Macaray William S. Lind Martha Rosenberg Website of the Day March 10 , 2009 Franklin Spinney Vijay Prashad Stan Cox Zoltan Grossman Reuven Kaminer Jonathan Cook Dave Lindorff Brian McKenna Harvey Wasserman Corey Pein Website of the Day
March 9 , 2009 Pam Martens Ralph Nader Peter Lee Mike Whitney Peter Morici Dean Baker Steve Ault Stephen Lendman Farooq Sulehria Belén Fernández Website of the Day March 6-8 , 2009 Alexander Cockburn Chris Floyd Uri Avnery Dave Lindorff Mark Weisbrot David Ker Thomson Phil Aliff Rebekah Ward Tracey Briggs Dean Baker Daniel P. Wirt, M.D. Carl Finamore Wajahat Ali David Michael Green David Macaray Michael Dickinson Susie Day Bob Sommer Ben Sonnenberg David Yearsley DC Larson Lorenzo Wolff Poets' Basement Website of the Weekend March 5 , 2009 James G. Abourezk Kathleen and Bill Christison Robert Weissman Patrick Cockburn William Blum Robert Fantina Saul Landau Benjamin Dangl Christopher Brauchli Website of the Day March 4, 2009 Marjorie Cohn Mike Whitney Ron Jacobs Ashley Smith Joanne Mariner Dan Bacher Mark Engler Franklin Lamb Cal Winslow David Mandelzys Website of the Day March 3, 2009 Conn Hallinan Fawzia Afzal-Khan Brian M. Downing Robert Larson Daniel P. Wirt, MD Russell Mokhiber William Loren Katz Kathy Sanborn Pauline Imbach Christopher Ketcham Website of the Day March 2, 2009 Andrea Peacock Paul Craig Roberts Peter Lee John Blair Peter Morici Uri Avnery Michael Donnelly Fred Gardner Sonia Nettnin Andrew Lehman Website of the Day
Feb. 27 - March 1, 2009 Alexander Cockburn Harry Browne Anthony DiMaggio Sasan Fayazmanesh Mischa Gaus Felice Pace Mike Whitney Lee Sustar Peter Lee Nicole Colson Roger Burbach Rannie Amiri Missy Beattie Dave Lindorff Robert David Steele Vivas John Ross Ralph Nader Yves Engler Alan Farago Zulfikar Majid David Yearsley Charles R. Larson Kim Nicolini Lorenzo Wolff Poets' Basement Website of the Weekend February 26, 2009 Dave Lindorff Jonathan Cook Patrick Cockburn Mike Whitney Eamonn McCann Tim Wise Tom Barry Harvey Wasserman Adam Turl David Macaray James McEnteer Website of the Day
February 25, 2009 Chris Sands M. Shahid Alam Chris Floyd Dave Lindorff Norman Solomon Rachel Godfrey Wood Niranjan Ramakrishnan Ron Jacobs Nadia Hijab Dennis Loo Website of the Day February 24, 2009 Paul Craig Roberts Uri Avnery Peter Morici Jonathan Cook Paul Fitzgerald / Andy Worthington Brian Horejsi Julia Stein Norm Kent Rachel Smolker / Dennis Loo James McEnteer Website of the Day February 23, 2009 Michael Hudson Mike Roselle Patrick Cockburn Franklin Spinney Einar Már Guðmundsson Ralph Nader Jordan Flaherty Helen Redmond Dennis Loo Harvey Wasserman Terry Lodge Website of the Day February 20 / 22, 2009 Alexander Cockburn Michael Neumann / Ismael Hossein-zadeh Paul Craig Roberts Linn Washington Jr. Saul Landau Marjorie Cohn Binoy Kampmark Dave Lindorff David Yearsley David Macaray James McEnteer Rick Salutin Wayne Clark Richard Rhames Stephen Martin Mitu Sengupta Charles R. Larson Richard Morse Lorenzo Wolff Poets' Basement Website of the Weekend February 19, 2009 Norman Finkelstein Harry Browne Robert Bryce Brian M. Downing Fred Gardner Andy Worthington Wajahat Ali Laura Carlsen Deb Reich Christopher Ketcham Website of the Day February 18, 2009 Paul Craig Roberts Mike Whitney M. Shahid Alam Patrick Cockburn Conn Hallinan Dave Lindorff Rannie Amiri Gareth Porter Eric Hobsbawm Christopher Brauchli Martha Rosenberg Website of the Day February 17, 2009 Michael Hudson Mike Whitney Ralph Nader Joanne Mariner John Ross Belén Fernández Mats Svensson David Macaray Gregory Vickrey M. Junaid Levesque-Alam Michael Dickinson Website of the Day February 16, 2009 Patrick Cockburn Oscar Guardiola-Rivera Paul Craig Roberts Uri Avnery P. Sainath Dedrick Muhammad / Michael Brown Carla Blank Patrick Irelan Dan Bacher Fidel Castro Harvey Wasserman Website of the Day February 13 - 15, 2009 Alexander Cockburn Joshua Frank Mike Whitney George Ciccariello-Maher Nikolas Kozloff Brian M. Downing Paul Craig Roberts Christopher Ketcham Ron Jacobs Dave Lindorff Alan Maass Chuck Spinney Phil Gasper Stephen Lendman Charles Thomson Kathy Sanborn Saul Landau Len Wengraf Harvey Wasserman David Macaray Tom Stephens Seth Sandronsky David Yearsley Lorenzo Wolff Kim Nicolini Poets' Basement Website of the Weekend
|
March 13 / 15, 2009 This Changes EverythingCannabidiol Now!By FRED GARDNER Two plants strains relatively rich in cannabidiol (CBD) have been identified by an analytic test lab recently established to serve the medical cannabis industry in California. That's two major stories in one sentence. Let's take it from the bottom… In December a lab in the East Bay started testing samples of cannabis for pathogenic mold and the presence of three cannabinoids –THC, CBD and CBN (cannabinol). THC is the main psychoactive compound in the cannabis plant. CBD is a cannabinoid with intriguing medical potential that gets bred out of cannabis when the breeder's goal is high THC content (as it has been in California for generations). CBN is a breakdown product of THC, an indicator of time in storage. The lab has been testing about 10 samples a day provided by Oakland's Harborside Health Center, whose proprietor, Steve DeAngelo, helped plan and underwrite the venture. Results from the lab are posted on labels affixed to the strains in Harborside's display cases. Thus prospective buyers are informed that the sparkly nuggets of Raspberry Kush they are savoring in a Petri dish are free of dangerous aspergillus and contain 14.3% THC by weight. (Percent CBD and CBN almost always round off to zero. That's about to change.) DeAngelo's primary goal is to impose safety standards industry-wide. "We're giving the analytic laboratory project a beta rollout," he says, "to find the problems and eliminate them before seriously soliciting participation from other dispensaries. Then we'll see who's serious about the medical paradigm." Running the lab are two 30-something entrepreneurs, D.L. and A.D, who spent about a year setting it up and refining their procedures under the tutelage of a sympathetic university-connected chemist. D.L. operates the gas chromatograph-mass spectrometer. A.L. is liaison to the dispensaries. They are planning to add tests for pesticides and certain terpenes –aromatic compounds that contribute to the effects of cannabis. The advent of a test lab will change the medical cannabis industry in significant ways. For some growers and distributors thriving under the status quo, the documented presence of toxins in their products will force adjustments. The lab has found levels of mold and e coli that bear witness to unsanitary production methods. Deangelo says, "It can't be the whole family and friends sitting around with all the dogs in the living room. We're putting out the message: 'Clean up your trim areas, clean up your storage areas, do not have cannabis curing in an area that's exposed to animals. Set up a clean room and put on different clothes when you go in. Wear gloves. Wash your hands. In other words, remember that your product is medicine and treat it as medicine.'" Harborside's savvy purchasing agent, Rick Pfrommer, notes that input from the lab has already led to growers cleaning up their acts. "Most of the people who have had mold in their cannabis are the people who didn’t have filters on their air intake. They may have had beautiful medicine, but they were pulling in whatever from the air. Now they've got filters." When the lab begins testing for pesticides, indoor growers who have been using chemicals to kill mites and other pests will have to find organic alternatives or else peddle their wares to dispensaries that don't adopt safety standards. Expect some to argue that a little residual Avid on their cannabis buds isn't going to hurt anyone. Eureka! (No, Laytonville!) CBD predominates over THC in cannabis that grows wild (ditchweed) and plants grown for fiber (hemp). When plants are bred for psychoactivity CBD is replaced by THC because the same gene codes for one or the other cannabinoid. According to research done in Europe and Israel, CBD has anti-inflammatory, anti-convulsant, anti-psychotic, anti-oxidant, and neuroprotective properties. It also has a direct inhibitory effect on certain cancer cells. Biologists at California Pacific Medical Center, Sean McAllister and Pierre Desprez, have determined that CBD inhibits breast cancer metastasis by suppressing a gene called Id-1. This winter they started working with mouse models of breast cancer, and if all goes well, they will be conducting clinical trial at CPMC in less than two years. A British company, GW Pharmaceuticals, has developed a high-CBD strain that it mixes with a high-THC strain to make Sativex, a plant extract formulated for spraying under the tongue that has been approved in Canada and elsewhere to treat neuropathic pain. CBD evidently bolsters the pain-killing effects of THC while moderating its psychoactivity. In various studies, patients with severe pain have reported getting significantly more relief from Sativex, the mixture, than from GW's high-THC extract. With a few notable exceptions the California cannabis samples tested to date have contained only trace amounts of CBD. The first notable exception exception occurred in late February when D.L. saw a spike on a computer-generated graph indicating a high level of CBD in one of the samples provided by Harborside. After some additional testing he confirmed that this strain, produced indoors in San Francisco, contained 4.2% CBD (and 8.9% THC) by weight. DeAngelo promptly made arrangements with the grower to rev up production. Buds and clones from the strain of interest should be available at Harborside within months. "It would be immoral to try to hoard the genetic material," says Deangelo. As this story goes off to CounterPunch March 12, a second high-CBD strain has been identified, grown outdoors in Mendocino County. It is a little more than five percent CBD by weight. Thus the medical marijuana movement/industry is entering a new stage. Growers will develop strains with higher CBD to THC ratios. Pro-cannabis doctors, who have long awaited high-CBD strains, are already planning rudimentary clinical trials to determine whether and in what ways high-CBD cannabis is beneficial. Because CBD counters the anxiety induced by THC, a high-CBD strain might prove palatable to many people who dislike the way marijuana makes them feel. High-CBD strains might also enable patients who need megadoses to ingest them while remaining functional. According to Jeffrey Hergenrather, MD, "Patients with certain cancers, ulcerative colitis and Crohn's Disease, seizure disorders... they all need to maintain a higher blood level of cannabinoids than is convenient with our high-THC strains. For them, development of a high-CBD strain could be a life or death matter." Whatever the outcome of clinical trials involving CBD, the effort alone -the attempt to produce and evaluate less psychoactive strains of marijuans- will refute the image of stoners paying lip-service to medical use that has tarnished the industry. And if and when the effectiveness of high-CBD cannabis in treating, say, rheumatoid arthritis, can be established, a wave of older Californians will be asking their doctors if cannabis is right for them. Fred Gardner edits O’Shaughnessy’s, the journal of cannabis in clinical practice. He can be reached at fred@plebesite.com
|
Now Available from CounterPunch Books! Spell Albuquerque: Waiting for
Lightning
|